Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study

PLSE has begun patient enrollment in its NANOPULSE-AF pivotal study, a key step toward potential approval of its NPS technology for atrial fibrillation treatment. The update advances the program into a late-stage clinical milestone that could open access to a large cardiac market. The news is positive for the company, though still clinical-development stage rather than a confirmed regulatory or commercial win.

Analysis

PLSE has begun patient enrollment in its NANOPULSE-AF pivotal study, a key step toward potential approval of its NPS technology for atrial fibrillation treatment. The update advances the program into a late-stage clinical milestone that could open access to a large cardiac market. The news is positive for the company, though still clinical-development stage rather than a confirmed regulatory or commercial win.